Controlling NFAT1 in T cells using engineered ncRNA transcriptional regulators

使用工程化 ncRNA 转录调节因子控制 T 细胞中的 NFAT1

基本信息

  • 批准号:
    7632171
  • 负责人:
  • 金额:
    $ 26.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-06-15 至 2011-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): During an immune response the expression of many genes is either upregulated or downregulated at the level of transcription, the process by which the DNA in genes is copied into mRNA. In T cells, the transcriptional activator NFAT1 controls the transcription of many genes important in the response to foreign antigen and plays critical roles in immune diseases. The broad objective of the proposed research is to design and engineer three types of non-coding RNA (ncRNA) molecules that can be used to either enhance or inhibit mRNA transcription in T cells by being brought to genes normally controlled by NFAT1. In addition to creating a new class of gene-specific ncRNA transcriptional regulators (no similar approach to controlling gene expression currently exists), these studies will reveal the extent to which NFAT1 contributes to the transcriptional program that occurs when T cells are activated, and identify genes not previously known to be directly regulated by NFAT1. The results of these studies will provide new insight into transcriptional control by NFAT1 in T cells, which is vitally important in understanding the normal immune response, as well as the inappropriate immune system responses that occur during autoimmune disorders, asthma, and allergy. The aims of the proposal are: Specific Aim 1. Create ncRNA transcriptional regulators that target human NFAT1. RNA molecules that bind NFAT1 will be isolated, and then fused to ncRNA domains previously shown to regulate transcription. These chimeric ncRNAs will be optimized to activate or repress NFAT1-driven transcription at a model gene in human T cells. Specific Aim 2. Study how an NFAT1-specific engineered ncRNA controls genome-wide transcription in T cells. To determine the efficacy and specificity with which an engineered chimeric ncRNA modulates genome-wide transcription in T cells, we will use expression and promoter microarrays. These experiments will reveal the complement of genes directly regulated by the engineered ncRNA, and by extension NFAT1. The innovation in these studies arises from the use of engineered ncRNAs to change the transcriptional program set by NFAT1 when T cells are activated. This approach is unique from conventional techniques to study the function of a transcription factor in cells, which typically lower or eliminate a protein. Rather, this approach uses NFAT1 to direct regulatory ncRNAs to the promoters of specific genes. These studies will provide the basis for creating ncRNA transcriptional regulators that target other mammalian transcription factors. In addition, the ncRNAs we develop could be used as lead compounds for the discovery of a new class of immune-therapeutics. PROJECT NARRATIVE: Properly controlling gene expression is essential to sustaining life and avoiding many diseases and cancers. The studies described here are aimed at engineering a new class of molecules that will either enhance or repress expression of specific genes in human T cells during the immune response. These studies will test a new approach to controlling gene expression in human cells and provide the groundwork needed to engineer additional molecules to control expression of genes important to growth, development, and disease in human cells.
描述(由申请人提供):在免疫应答期间,许多基因的表达在转录水平上上调或下调,基因中的DNA被复制成mRNA的过程。在T细胞中,转录激活因子NFAT1控制许多对外来抗原应答重要的基因的转录,并在免疫疾病中发挥关键作用。该研究的主要目标是设计和制造三种类型的非编码RNA (ncRNA)分子,通过将其带入通常由NFAT1控制的基因中,可用于增强或抑制T细胞中的mRNA转录。除了创建一类新的基因特异性ncRNA转录调节因子(目前还没有类似的方法来控制基因表达),这些研究将揭示NFAT1对T细胞活化时发生的转录程序的贡献程度,并鉴定以前不知道由NFAT1直接调节的基因。这些研究结果将为T细胞中NFAT1的转录控制提供新的见解,这对于理解正常免疫反应以及自身免疫性疾病、哮喘和过敏期间发生的不适当免疫系统反应至关重要。提案的目标是:具体目标1。创建针对人类NFAT1的ncRNA转录调控因子。结合NFAT1的RNA分子将被分离,然后融合到先前显示的调节转录的ncRNA结构域。这些嵌合ncrna将被优化以激活或抑制人类T细胞模型基因上nfat1驱动的转录。具体目标2。研究nfat1特异性工程ncRNA如何控制T细胞全基因组转录。为了确定工程嵌合ncRNA调节T细胞全基因组转录的有效性和特异性,我们将使用表达和启动子微阵列。这些实验将揭示由工程ncRNA直接调控的基因的补充,并通过扩展NFAT1。这些研究的创新之处在于,当T细胞被激活时,利用工程化的ncrna改变由NFAT1设定的转录程序。这种方法与研究细胞中转录因子功能的传统技术相比是独特的,转录因子通常会降低或消除蛋白质。相反,这种方法使用NFAT1将调节性ncrna引导到特定基因的启动子上。这些研究将为创建针对其他哺乳动物转录因子的ncRNA转录调节因子提供基础。此外,我们开发的ncrna可以用作发现一类新的免疫疗法的先导化合物。项目简介:适当控制基因表达对维持生命和避免许多疾病和癌症至关重要。这里描述的研究旨在设计一类新的分子,这些分子将在免疫反应期间增强或抑制人类T细胞中特定基因的表达。这些研究将测试一种控制人类细胞中基因表达的新方法,并为设计额外的分子来控制对人类细胞生长、发育和疾病重要的基因表达提供必要的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jennifer F. Kugel其他文献

Non-coding-RNA regulators of RNA polymerase II transcription
RNA 聚合酶 II 转录的非编码 RNA 调节因子
  • DOI:
    10.1038/nrm1946
  • 发表时间:
    2006-05-24
  • 期刊:
  • 影响因子:
    90.200
  • 作者:
    James A. Goodrich;Jennifer F. Kugel
  • 通讯作者:
    Jennifer F. Kugel
Correction for Abrisch et al., Infection by Herpes Simplex Virus 1 Causes Near-Complete Loss of RNA Polymerase II Occupancy on the Host Cell Genome
更正 Abrisch 等人,单纯疱疹病毒 1 感染导致宿主细胞基因组上 RNA 聚合酶 II 占据几乎完全丧失
  • DOI:
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Robert G. Abrisch;Tess M. Eidem;Petro Yakovchuk;Jennifer F. Kugel;J. Goodrich
  • 通讯作者:
    J. Goodrich
Release of human TFIIB from actively transcribing complexes is triggered upon synthesis of 7 nt and 9 nt RNAs
7 nt 和 9 nt RNA 合成后,触发主动转录复合物释放人 TFIIB
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Elina Ly;Abigail E Powell;J. Goodrich;Jennifer F. Kugel
  • 通讯作者:
    Jennifer F. Kugel
In vitro studies of the early steps of RNA synthesis by human RNA polymerase II.
人 RNA 聚合酶 II 合成 RNA 早期步骤的体外研究。
  • DOI:
    10.1016/s0076-6879(03)70056-1
  • 发表时间:
    2003
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jennifer F. Kugel;J. Goodrich
  • 通讯作者:
    J. Goodrich
Single molecule FRET shows uniformity in TBP-induced DNA bending and heterogeneity in bending kinetics †
单分子 FRET 显示 TBP 诱导的 DNA 弯曲的均匀性和弯曲动力学的异质性 †
  • DOI:
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Rebecca H. Blair;J. Goodrich;Jennifer F. Kugel
  • 通讯作者:
    Jennifer F. Kugel

Jennifer F. Kugel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jennifer F. Kugel', 18)}}的其他基金

Unraveling the biological roles of specific miRNAs, from experimental target identification through functional characterization
从实验目标识别到功能表征,揭示特定 miRNA 的生物学作用
  • 批准号:
    10566442
  • 财政年份:
    2023
  • 资助金额:
    $ 26.09万
  • 项目类别:
Defining the Genome-wide Alcohol-induced Transcriptional Changes in Breast Cancer
定义酒精诱导的乳腺癌全基因组转录变化
  • 批准号:
    9761407
  • 财政年份:
    2018
  • 资助金额:
    $ 26.09万
  • 项目类别:
Identify the Transcriptome and Proteome Associated with miRNAs dring Myogenesis
鉴定与肌发生过程中 miRNA 相关的转录组和蛋白质组
  • 批准号:
    8866691
  • 财政年份:
    2015
  • 资助金额:
    $ 26.09万
  • 项目类别:
Identify the Transcriptome and Proteome Associated with miRNAs dring Myogenesis
鉴定与肌发生过程中 miRNA 相关的转录组和蛋白质组
  • 批准号:
    9038986
  • 财政年份:
    2015
  • 资助金额:
    $ 26.09万
  • 项目类别:
Controlling NFAT1 in T cells using engineered ncRNA transcriptional regulators
使用工程化 ncRNA 转录调节因子控制 T 细胞中的 NFAT1
  • 批准号:
    7509919
  • 财政年份:
    2008
  • 资助金额:
    $ 26.09万
  • 项目类别:

相似海外基金

Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
  • 批准号:
    2901112
  • 财政年份:
    2024
  • 资助金额:
    $ 26.09万
  • 项目类别:
    Studentship
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
  • 批准号:
    485322
  • 财政年份:
    2023
  • 资助金额:
    $ 26.09万
  • 项目类别:
    Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
  • 批准号:
    493135
  • 财政年份:
    2023
  • 资助金额:
    $ 26.09万
  • 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
  • 批准号:
    493526
  • 财政年份:
    2023
  • 资助金额:
    $ 26.09万
  • 项目类别:
    Operating Grants
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
  • 批准号:
    495593
  • 财政年份:
    2023
  • 资助金额:
    $ 26.09万
  • 项目类别:
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
  • 批准号:
    485504
  • 财政年份:
    2023
  • 资助金额:
    $ 26.09万
  • 项目类别:
    Salary Programs
Mechanistic Study of Inspiratory Training in Childhood Asthma
儿童哮喘吸气训练机制研究
  • 批准号:
    10637048
  • 财政年份:
    2023
  • 资助金额:
    $ 26.09万
  • 项目类别:
Early life exposure to metal mixtures: impacts on asthma and lungdevelopment
生命早期接触金属混合物:对哮喘和肺部发育的影响
  • 批准号:
    10678307
  • 财政年份:
    2023
  • 资助金额:
    $ 26.09万
  • 项目类别:
Lung resident Treg suppression of Th2 resident memory T cells in allergic asthma
过敏性哮喘中肺常驻 Treg 对 Th2 常驻记忆 T 细胞的抑制
  • 批准号:
    10664599
  • 财政年份:
    2023
  • 资助金额:
    $ 26.09万
  • 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
  • 批准号:
    10813753
  • 财政年份:
    2023
  • 资助金额:
    $ 26.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了